There's no doubt about it - last week's failure to pass the American Health Care Act was a painful setback in the fight to repeal and replace Obamacare, wrote Sally Pipes in the Washington Examiner’s Beltway Confidential blog.
But Obamacare's critics need not give up. There are plenty of executive actions the Trump administration could take to roll back the Affordable Care Act. First among them should be refusing to fund Obamacare's "cost-sharing reduction" subsidies - federal dollars that reimburse insurance companies for covering many of the out-of-pocket costs of low-income exchange enrollees.
These reimbursements are expensive - some $7 billion a year. But they're also illegal, she states.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze